300347 泰格医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入5,025,868-0.82%6,603,1207,384,0397,085,4715,213,538
减:营业总成本4,559,52713.24%5,610,0485,554,1255,156,5443,637,765
    其中:营业成本3,560,25214.95%4,361,1074,535,5114,277,0082,942,883
               财务费用76,160142.77%38,067(108,324)(158,124)(216,363)
               资产减值损失(5,402)-49.31%1,255(29,725)(2,416)(12,915)
公允价值变动收益323,191-1,039.18%(501,688)352,771535,8571,815,390
投资收益440,221303.29%166,642338,175102,751312,283
    其中:对联营企业和合营企业的投资收益----31,271105,18339,76314,348
营业利润1,229,00913.27%664,4192,486,9412,582,3993,696,967
利润总额1,222,78112.48%664,4622,488,5332,585,3773,684,566
减:所得税费用131,100-28.72%216,630338,606313,652292,864
净利润1,091,68120.88%447,8312,149,9272,271,7253,391,702
减:非控股权益71,247-20.58%42,688125,077265,173517,539
股东净利润1,020,43425.45%405,1432,024,8502,006,5522,874,163

市场价值指针
每股收益 (元) *1.19026.60%0.4702.3402.3203.310
每股派息 (元) *----0.3000.5680.5500.500
每股净资产 (元) *24.5940.99%23.89824.10222.44720.774
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容